Online citations, reference lists, and bibliographies.
← Back to Search

Pharmaceutical Formulations Of Anthralin

M. Whitefield
Published 1981 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
A therapeutic action can occur only if the drug reaches the receptor sites in sufficient quantities. It is important, therefore, to ensure that the base does not interact with the drug thereby impeding its release, e.g. by complexing due to hydrogen bonding. On the contrary, the drug should have a much greater physico-chemical affinity for the skin substrate than it does for the base in which it is formulated. In addition, the drug particles in the base should have a minimum particle size to provide the maximum surface area for reactivity and optimal biological effectiveness. The best system is, therefore, a molecular dispersion in true solution. However, this advantage must not be outweighed by an affinity of the solvent molecules for the drug solute molecules so that the most efficient system will be provided by employing a solvent in which the solute is only poorly soluble but sufficiently so to provide enough drug in solution at saturation for therapeutic response. In order to ensure saturation over a range of tetnperatures it is preferable to include an excess of drug in the form of an amorphous or microcrystalline dispersion to provide a depot for rapid further dissolution. This also maintains saturation after the dissolved drug molecules start to partition into the skin substrate.
This paper references



This paper is referenced by
10.1111/j.1365-2133.1982.tb04563.x
Zoon's (plasma‐cell) balanitis: treatment by circumcision
T. Sonnex (1982)
10.1016/S0378-5173(01)00810-9
Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol.
R. Agarwal (2001)
10.1111/j.1365-4362.1994.tb01005.x
EFFICACY OF SHORT‐CONTACT THERAPY WITH DITHRANOL IN CHILDHOOD PSORIASIS
A. Zvulunov (1994)
Dermatological preparations for the tropics. A formulary of dermatological preparations and background information on choices, production and dispensing.
P. Bakker (2012)
10.1016/S0190-9622(83)70125-8
Anthralin: historical and current perspectives.
R. Ashton (1983)
10.1111/J.1600-0536.1988.TB02762.X
Patch testing with dithranol and its degradation products
P. G. Green (1988)
10.1111/j.1600-0536.1992.tb03282.x
Dithranol allergy: fact or fiction?
A. Burden (1992)
10.1016/0022-202X(89)90181-4
Investigations of anthralin free radicals in model systems and in skin of hairless mice.
J. Fuchs (1989)
10.1111/j.1440-0960.1982.tb00743.x
DITHRANOL IN A CREAM BASE IN THE TREATMENT OF PSORIASIS
O. Wargon (1982)
10.33786/JCPR.2015.V06I01.004
Development and Evaluation of Novel Topical Formulation by Minimizing Side Effect of Dithranol for Skin Diseases
. S.D.Mhaske (2015)
10.1002/9781444317633.CH73
73. Topical Therapy
J. B. F. C. Dermatologist (2010)
10.1016/0041-008X(91)90326-A
Dithranol-induced cytotoxicity in primary cultures of rat epidermal keratinocytes. I. The role of reactive oxygen species.
G. Hsieh (1991)
10.1111/j.1365-4362.1994.tb01006.x
Orbital Emphysema
Scott L. Lee (2006)
10.1016/0748-5514(85)90135-7
Antipsoriatic drug action of anthralin: oxidation reactions with peroxidizing lipids.
F. Ducret (1985)
10.1007/BF00638239
Steroids versus nonsteroids in the treatment of cutaneous inflammation: therapeutic modalities for office use
E. Panconesi (2004)
10.1016/S0190-9622(87)70125-X
Anthralin stability in various vehicles.
P. G. Green (1987)
10.1016/S0950-3579(94)80020-0
Skin lesions in psoriasis.
M. Goodfield (1994)
10.1016/S0378-5173(98)00089-1
Preparation and study of the characteristics of dithranol:polyvinylpyrrolidone coevaporates
I. Delneuville (1998)
A stability study of dithranol in solution, formulations and in normal and psoriatic skin
P. Lubwika (1994)
10.1080/09546630601028729
A randomized, double‐blind, vehicle‐controlled study of a novel liposomal dithranol formulation in psoriasis
A. Saraswat (2007)
10.1111/j.1365-4632.2012.05611.x
Anthralin/dithranol in dermatology
V. Sehgal (2014)
10.3109/03639048809151898
Decomposition of Anthralin in Alkaline Solutions
S. M. Upadrashta (1988)
10.1016/0163-7258(92)90051-Z
Multistage carcinogenesis in mouse skin.
J. DiGiovanni (1992)
10.1111/j.1365-2710.1990.tb00406.x
STABILITY OF A NOVEL DITHRANOL OINTMENT FORMULATION, CONTAINING ASCORBYL PALMITATE AS AN ANTI‐OXIDANT
P. Weller (1990)
10.1002/9781118441213.RTD0018
Principles of Topical Therapy
J. Berth-Jones (2016)
Semantic Scholar Logo Some data provided by SemanticScholar